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Aims Unloading-promoted reversal of heart failure (HF) allows long-term transplant-free outcome after ventricular assist
device (VAD) removal. However, because few patients with chronic cardiomyopathy (CCM) were weaned from
VADs (the majority only recently), the reliability of criteria used for weaning decisions to predict long-term post-
weaning success is barely known. After 15 years of weaning experience, we assessed this issue.
Methods and
results
In 47 patients with CCM as the underlying cause for HF, who were part of a total of 90 patients weaned from bridge-
to-transplant-designed VADs since 1995, we analysed data on cardiac morphology and function collected before VAD
implantation, echocardiographic parameters recorded during ‘off-pump’ trials, duration of HF before implantation,
and stability of recovery before and early after VAD removal. Post-weaning 5 year freedom from HF recurrence
reached 66%. Only ﬁve patients (10.6%) died due to HF recurrence or weaning-related complications. Pre-explanta-
tion off-pump left ventricular ejection fraction (LVEF) of ≥50 and ≥45% revealed predictive values for cardiac stab-
ility lasting ≥5 years after VAD removal of 91.7 and 79.1%, respectively. With each unit of LVEF reduction, the risk of
HF recurrence became 1.5 times higher. The predictive value of LVEF ≥45% also became .90% if additional par-
ameters like pre-explantation LV size and geometry, stability of unloading-induced cardiac improvement before
VAD removal, and HF duration before VAD implantation were also considered. Deﬁnite cut-off values for certain
parameters (including tissue-Doppler-derived LV wall motion velocity) allowed formulation of weaning criteria
with high predictability for post-weaning stability, also in patients with incomplete cardiac recovery.
Conclusions Ventricular assist device removal in CCM patients is feasible and can be successful even after incomplete cardiac
recovery. Parameters of pre-explantation cardiac function, LV size and geometry, their stability during ﬁnal off-pump
trials, and HF duration allow detection of patients with the potential to remain stable for .5 post-weaning years.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Ventricular assist devices (VADs), which were primarily designed for
bridge-to-transplant therapy, are today also used as permanent
therapy for end-stage heart failure (HF). Evidence of myocardial
reverse remodelling and functional improvement during VAD
support in some patients suggests that the use of mechanical ventri-
cular unloading as a therapeutic strategy aimed at cardiac recovery,
allowing VAD removal instead of heart transplantation (HTx), may
be another potential future indication for VAD implantation.
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doi:10.1093/eurheartj/ehq353During VAD support, cardiac improvement to levels that allow
VAD removal instead of HTx is less frequent than myocardial
recovery at molecular and cellular levels, which has more often
been shown under these circumstances.
2,3,7,13,14 Recovery
appears to be related to the aetiology of myocardial damage and
the duration of heart disease.
2,15,16 More often, cardiac recovery
allowing weaning from VADs was detected after acute myocarditis
and post-cardiotomy HF, but recovery with long-term cardiac
stability is also possible in idiopathic dilated cardiomyopathy
(IDCM).
4–6,9,11,15–19 However, greatly differing recovery rates
during VAD support have been reported, especially for
IDCM.
12,16,18–20 These may arise from different weaning criteria,
different medical treatments during mechanical unloading, differ-
ences in mechanical systems used for ventricular support, and
also differences in patient selection for VAD implantation.
So far only a few patients with chronic myocardial failure had
been weaned from VADs and the majority were weaned only
recently, i.e. during the past 3–5 years.
2,6,16–21 However, if
cardiac recovery is detected, it is essential to have reliable tools
for the prediction of cardiac stability in the case of VAD
removal. Therefore, data from weaned patients, especially from
those with cardiac stability for .5 years after VAD explantation,
are necessary to improve future weaning decisions. The low rate
of myocardial recovery even at incomplete levels and the fact
that weaning is possible only after relevant cardiac improvement
limit the possibilities for prospective studies on myocardial recov-
ery during ventricular unloading.
PreviousevaluationofourIDCMpatientswithLVADsshowedthat
certain ‘off-pump’ echocardiographic data are reliable for the detec-
tion of cardiac recovery with the potential for medium-term stability
after LVAD removal.
5,16 Meanwhile, a larger number of our patients
with chronic cardiomyopathy (CCM), including clinical entities
other than IDCM, have reached post-weaning cardiac stability for
between 5 and 15 years and it has become possible to investigate
whether long-term stability can be reliably predicted before VAD
removal for this larger and less homogeneous patient cohort. The
present study aimed to identify both weaning criteria that can
predict long-term cardiac stability after VAD removal and major
risk factors for HF recurrence in patients with unloading-induced
myocardial recovery from end-stage HF linked to CCM.
Methods
Patients evaluated
Between March 1995 and February 2010, a total of 90 patients who
received emergency VAD implantation because of life-threatening HF
unresponsive to medical treatment, including inotropic support,
were weaned from VADs after cardiac improvement, which was
deemed sufﬁcient to allow VAD removal with a low risk of short-term
recurrence of HF. Among these patients, we selected for evaluation
those with CCM as the underlying cause for HF. Patients weaned
from VADs after recovery from post-cardiotomy HF, acute myocar-
ditis, and acute myocardial infarction and also children younger than
14 years of age were excluded from the study.
Inclusion criteria were fulﬁlled by 47 patients who consented to
VAD implantation as a bridge to transplantation and provided
written informed consent before VAD removal. Of these, 41
(87.2%) had IDCM, 4 (8.5%) had histological evidence of chronic myo-
carditis before VAD implantation, and 2 (4.3%) had chronic ischaemic
cardiomyopathy with severe LV dilation. Before VAD insertion, all
patients had irreversible end-stage HF and required continuous posi-
tive inotropic support. No attempts have been made to use VADs
electively with the aim of myocardial recovery only.
Of the 47 patients evaluated, 45 (95.7%) were weaned from LVADs
and only 2 (4.3%) from biventricular assist devices (BVADs). Of 45
explanted LVADs, 33 (70.2%) were pulsatile pumps (Novacor, TCI, or
Berlin Heart EXCOR); the other 12 (29.8%) were ‘continuous ﬂow’
pumps (INCOR and HeartMate II). Pump explantation followed the fun-
damental rule of maintaining the recovered heart in as unmolested a
state as possible. Therefore, VAD removal was performed on the
beating heart. During VAD removal, we aimed as much as possible to
leave in place the intrathoracic part of both cannulas after they were
reliably occluded. Intrathoracic cannulas were removed only in 13
patients (10 with ‘continuous ﬂow’ LVADs and 3 with pulsatile
LVADs). In these 13 patients and other 2 patients with Heartmate II
LVADs, we used the heart–lung machine. Off-pump surgery was poss-
ible for the explantation of 32 pulsatile VADs (30 LVADs and 2 BVADs).
Study design and data collection
To assess the predictability of post-weaning outcome without HTx or
other VAD implantation and to identify risk factors for post-weaning
HF recurrence, we used the data collected before and during VAD
support.
Pre-implantation data were used to evaluate their potential useful-
ness for weaning decisions by the assessment of their predictive value
for post-weaning stability of unloading-induced cardiac improvement.
For this reason, we compared the pre-implantation data of weaned
patients with and without long-term post-weaning cardiac stability. Pre-
implantation data were collected from our database before VAD
removal and did not interfere with weaning decisions. In addition to
diagnosis and NYHA class, the duration of heart disease, ECG, and
echocardiographic data, as well as data provided by pre-implantation
right- and left-heart catheterization (including coronary angiography)
werecollectedforevaluation.Histologicaldataonmyocardialhypertro-
phy and interstitial ﬁbrosis obtained in all evaluated patients from apical
cores removed at VAD implantation were also collected for further
evaluation. Methodological details have been previously described.
1,9
After successfulweaningofthreeIDCM patientsfromLVADsin1995
who had off-pump left ventricular end-diastolic diameters (LVEDDs) of
,50 mm and ejection fraction (LVEF) of between 45 and 55%, we pre-
sumed that LVAD removal might be safely possible if, during repeated
off-pump trials, the maximum LVEDD was 55 mm and the minimum
LVEF 45%, while the right ventricular (RV) size and function remained
stable.Sincethen,off-pumpechocardiographicdatahavebeencollected
prospectively according to a well-established protocol, but until 2002
VAD removal was not absolutely limited to patients with normal LV
size and LVEF of .45%. Thus, nine patients with IDCM were weaned
from VADs although off-pump LVEDD was 56–66 mm and/or LVEF
30–44%. However, in ﬁve of these patients, VAD explantation was
prompted by pump-related complications (pump infection,
thrombo-embolism, bleeding complications). These ﬁvepatients under-
went VAD removal although cardiac improvement appeared less prom-
ising for long-term transplant-free outcome, but the risk of keeping
them on their VADs appeared to be higher than the risk of removing
the VADs with the option to perform HTx later (if necessary) after
the treatment of VAD-related complications.
In 2002, we changed our weaning protocol by limiting VAD
explantation to patients with off-pump LVEF ≥45% at LVEDD
≤55 mm, and no further VAD explantation was performed in patients
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of post-weaning outcome showed good results only in those with pre-
weaning off-pump LVEF ≥45% and LVEDD ≤55 mm. To verify these
preliminary ﬁndings, we also compared the post-weaning outcome of
patients who were weaned before March 2002 with that of those
weaned thereafter. Table 1 show our main weaning criteria used
after March 2002.
Pharmacological therapy
During ventricular unloading, all patients were treated with beta-
blockers (metoprolol or carvedilol), angiotensin-converting enzyme
(ACE)-inhibitors (enalapril, ramipril, or lisinopril), aldosterone antag-
onists (spironolactone), loop diuretics (furosemide or torasemide),
and digitalis. Medication doses were individually adapted to reduce
heart rate (HR) towards 55–60 b.p.m. and blood pressure to the
lowest optimally tolerated value, as well as to maintain optimal renal
function. However, after the detection of cardiac improvement
which was deemed sufﬁcient to consider a patient as a potential
weaning candidate, in those with off-pump systemic arterial diastolic
pressure values ,55 mmHg, we reduced the doses of ACE-inhibitors
and diuretics. The aim was to increase the diastolic pressure to values
of between 55 and 65 mmHg, which provided a more suitable after-
load for the evaluation of LV systolic function. Treatment with beta-
blockers, ACE-inhibitors, spironolactone, and low-dose loop diuretics
was continued after VAD removal. In patients with post-weaning
cardiac stability, coumadin anticoagulation therapy was maintained
for 6–12 months after VAD removal [international normalized ratio
(INR) 2–3]. Thereafter, stable patients were switched to Aspirin
(daily 100 mg for at least 2 years).
Assessment of cardiac recovery
After VAD implantation and before patients were discharged home,
the effect of unloading on cardiac size, shape, and function was mon-
itored weekly by echocardiography. Thereafter, the frequency of
follow-up examinations varied between 1 and 4 weeks. Since 1999,
in addition to conventional echocardiography, tissue Doppler imaging
(TDI) was also used to assess ventricular function. For the evaluation
of LV recovery, we measured the systolic wall motion peak velocity
(Sm) at the basal posterior wall. Methodological details of Sm measure-
ments were described previously.
16,22 To assess the RV systolic func-
tion, we measured the peak velocity of tricuspid annulus systolic
excursion (STA) at the level of the free wall.
Off-pump echocardiography at rest evaluating the heart for a short
time without VAD support under the same circumstances which will
exist after VAD removal was the cornerstone for the assessment of
cardiac recovery and for weaning decisions. Off-pump trials were
started after the LV reduced its end-diastolic diameter to 60 mm
and mitral regurgitation was ≤grade I. Before pump-stops, heparin
was given to prevent thrombus formation inside the pump. Heparin
doses varied between 60 and 100 IU/kg according to the pro-thrombin
time reported as INR. Patients with heparin-induced throbocytopenia
received Argatroban (synthetic direct thrombin inhibitor) infusions
(2 mg/kg/min), which were started 1 h before the off-pump trials.
For pulsatile LVADs, trials consisted of pump frequency reduction to
the lowest, followed by intermittent pump-stops lasting up to 15 min.
Additionally, during the off-pump periods, the device was allowed to
pump once a minute. In patients with axial ﬂow pumps, where stopping
or low rotor speed leads to retrograde ﬂow into the LV, which can be
misleading for the evaluation of cardiac function, we reduced the rotor
speed to values which result in a close to zero net ﬂow in one cardiac
cycle. In patients with BVADs, the RV pump was stopped 30 s earlier
than the LV pump and then both pumps remained inactive for up to
15 min to allow the evaluation of cardiac function. In patients with
cardiac improvement, such trials were conducted weekly until the
recovery reached its maximum and there was no further improvement.
At this point, the ﬁnal decision in favour of or against VAD explantation
was made. During recovery, as described previously, the working
mode of the pumps was also changed in order to exert moderate
load on the LV myocardium.
1,9 To avoid excessive stimulation of the
myocardium during recovery, stress echocardiography was not routi-
nely used. However, to avoid misleading overestimations of LV systolic
function induced by extremely low afterload, we aimed to perform the
ﬁnal off-pump trials at diastolic systemic blood pressure values not
below 55 mmHg.
Right-heart catheterization with ‘off-pump’ haemodynamic measure-
ments was routinely scheduled only for patients who were already
selected for VAD removal and was performed 1 h before VAD explan-
tation. Invasive haemodynamic measurements for the assessment of
cardiac recovery were not routinely performed.
To monitor myocyte recovery during ventricular unloading, in
patients with non-ischaemic CCM we also looked for anti-b1-
adrenoceptor auto-antibodies (A-b1-AABs) before VAD implantation,
and thereafter weekly during the entire period of VAD support. The
bioassay for A-b1-AAB measurement was described previously.
9,23
However, due to the lack of data on impact of A-b1-AAB disappearance
on cardiac recovery during ventricular unloading, weaning decisions
were made independently of A-b1-AAB measurement results.
Weaning decisions were also independent of histological data
obtained from myocardial tissue specimens before VAD implantation
because thereafter no routine biopsies for monitoring histological
changes during ventricular unloading were performed and also
because the impact of myocardial hypertrophy and interstitial ﬁbrosis
on the stability of unloading-promoted cardiac improvement was
barely known. Nevertheless, before, during, or early after VAD
removal, LV myocardial tissue specimens were obtained in 14 patients
(12 myocardial biopsies performed during thoracic surgery and 2
................................................................................
Table 1 Main weaning criteria used since March 2002
Examination Parameters and parameter-derived
measurements obtained during the
ﬁnal pre-explantation off-pump trial
a
Electrocardiography Sinus rhythm
HR ,90 b.p.m.
Not more than 25% HR increase during
off-pump trials
Brachial artery
pressure
Mean ≥65 mmHg
Echocardiography LVEDD ≤55 mm
LVEF ≥45%
No or maximum grade II mitral and/or
aortic valve regurgitation
No RV dilation (RVOT diameter ,35 mm,
short-/long-axis ratio ,0.6)
No or maximum grade II tricuspid or
pulmonary valve regurgitation
Right-heart
catheterization
Cardiac index .2.6 L/min/m
2
Pulmonary artery wedge pressure (mean)
,13 mmHg
Right atrial pressure (mean) ,10 mmHg
aMeasurements performed at rest, without any inotropic support.
M. Dandel et al. 1150endomyocardial biopsies obtained by arterial approach). In 10 other
patients, we performed RV endomyocardial biopsies by venous
approach before VAD removal. Histological data obtained from
these weaned patients were used for the assessment of
unloading-induced myocardial changes.
Post-weaning monitoring of cardiac function
Echocardiography remained the major tool for monitoring cardiac
function after VAD removal. During the ﬁrst post-weaning week, it
was performed daily, thereafter each second day. During rehabilitation,
it was performed weekly and in outpatients, the frequency of sched-
uled follow-up controls varied in accordance with the post-weaning
time between monthly and every 6 months.
Exercise tolerance was evaluated by a maximum (symptom-limited)
incremental treadmill exercise test according to Naughton’s protocol.
However, this test was not performed before 2–3 months post-
operatively. During the past 7 years, at each follow-up examination
NT-proBNP plasma levels were also measured.
Statistics
Statistical analysis was performed using SPSS 12.0 for Windows (SPSS,
Inc., Chicago, IL, USA). Quantitative data, representing patient charac-
teristics before VAD implantation and at the time of VAD removal,
were expressed as means and standard deviation (SD). However,
because we dealt with small data sets (small number of subjects)
with non-normally distributed data, differences between patients
with lasting recovery and those with recurrence of HF (independent
groups) were analysed using the non-parametric Mann–Whitney U
test and Fisher’s exact test. For all tests, differences between groups
were considered signiﬁcant for two-sided P-value ,0.05. Sensitivity,
speciﬁcity, and predictive values were calculated for selected echocar-
diographic parameters and time parameters related to HF history and
cardiac recovery during LVAD support according to pre-speciﬁed
cut-off points and were expressed as percentages. Kaplan–Meier
curves were applied for survival analysis and for freedom from HTx
after LVAD explantation. The probability of survival and the probability
of freedom from HTx at a given point of time as derived from the
Kaplan–Meier estimation were expressed in percent+standard
error (SE). Univariate logistic regression was used to calculate odds
ratios with 95% CI for main risk factors. Cox regression was also
used to analyse the relevance of major risk factors. For Kaplan–
Meier estimates of overall survival, we introduced into the analyses
the time of survival after VAD removal (including the survival time
after HTx), whereas for the Kaplan–Meier estimates of freedom
from HF recurrence, we used only the time between VAD removal
and reappearance of HF signs and symptoms which make it necessary
to list the patient for HTx.
Results
Weaned patient characteristics at
ventricular assist device implantation
Of the 47 patients evaluated, 17 (36.2%) were ,40 years, 19
(40.4%) were 40–55 years, and 11 (23.4%) were between 56
and 65 years. Before VAD implantation, these patients had
dilated LV (LVEDD: 64–93 mm), LVEF between 10 and 20%,
mitral regurgitation ≥grade II, and high pulmonary arterial pressure
(PAP) values (mean 32–54 mmHg). The duration of HF before
VAD insertion was 4.1+3.8 years. None had undergone previous
resynchronization therapy. Weaned patient characteristics before
VAD implantation are shown in Table 2.
Clinical features at ventricular assist
device explantation
For the weaned CCM patients, the mean duration of ventricular
unloading necessary for maximum cardiac improvement allowing
VAD explantation was 4.9+2.8 months. Left ventricular ejection
fraction and LVEDD values measured during ﬁnal off-pump trials
before VAD removal ranged from 30 to 60% and from 40 to
64 mm, respectively. At VAD explantation, all patients had
normal PAP values, normal aortic valve function, and no or not rel-
evant mitral or tricuspid valve regurgitation (grade ≤I). In 38 of 39
weaned patients with non-ischaemic CCM who tested positive for
A-b1-AABs before VAD implantation, the auto-antibodies disap-
peared after 3–31 weeks of LV unloading. Comparative histomor-
phometry showed 18.1+13.3% reduction of the relative content
of ﬁbrosis during unloading. Reduction of ﬁbrosis in 64% and
regression of myocardial hypertrophy in 91% of the weaned
patients in whom comparative histology was possible were shown.
Outcome after ventricular assist device
explantation
None of the 47 weaned CCM patients was lost to follow-up after
VAD removal as long as they were alive. At the time of evaluation,
the fate of all 47 patients included in the study was well known.
The median follow-up after VAD removal was 5.7 years (range
0.1–14.8 years). Figure 1 shows a diagram giving the number of
weaned CCM patients at time points and their outcome, starting
from the time of VAD explantation.
Patient survival after ventricular assist
device explantation
At the time of evaluation, 33 (70.2%) of the 47 patients with end-
stage CCM before VAD implantation, who were weaned since
March 1995 from their VADs after different degrees of cardiac
recovery, were alive. Kaplan–Meier estimates of overall survival
after VAD removal (including post-HTx survival for those with
HF recurrence) revealed probabilities of 71.4+7.1 and 65.7+
7.6% for 5 and 10 year survival, respectively (Figure 2A). Of 14
patients who have died to date, 9 (64.3%) died due to different
causes not related to VAD removal. The vast majority of patients
with HF recurrence underwent HTx and thus, the assessment of
post-weaning survival from HF recurrence or weaning-related
complications by Kaplan–Meier estimates revealed high probabil-
ities for 5 and 10 year survival, reaching 88.4+5.7 and 85.8+
6.0%, respectively (Figure 2B). There was no between-group differ-
ence in the Kaplan–Meier estimates of overall survival for patients
with and without HF recurrence after VAD removal (10 year sur-
vival 64.7+ 11.6 and 67.1 + 9.7%, respectively; P ¼ 0.76).
Kaplan–Meier estimates of transplant-free survival after VAD
removal revealed probabilities of 68.9+7.6 and 61.6+8.6% for
5 and 10 year survival, respectively.
The complications related to VAD removal were uncommon.
Infection was a major problem in ﬁve patients, but in four of
these, it was already present before VAD removal. Bleeding
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bleeding 4 months after LVED removal). None of the patients
with the residual apical conduit left in place after LVAD removal
had stroke or extracerebral embolic complications arising from
the LV.
Of the 31 patients who were weaned before March 2002, 5
(16.1%) died due to complications related to VAD removal or
recurrence of HF, 2 (6.5%) died due to causes not related to
VAD removal, and 3 (9.6%) died after HTx. Of the 16 patients
with CCM who were weaned thereafter, when we used the modi-
ﬁed weaning protocol, 2 (12.5%) died during the ﬁrst 3 years after
weaning due to causes not related to VAD explantation and 2
(12.5%) died after HF recurrence beyond the ﬁfth post-weaning
(one before HTx, the other early after HTx).
Heart function after ventricular assist
device removal
To date, post-weaning recurrence of HF occurred in 17 (36.2%)
of the evaluated patients suffering from CCM before VAD
implantation (Figure 1). Myocardial dysfunction with progressive
LV dilation but not the new appearance or aggravation of pre-
existing mitral regurgitation appeared to be the cause for the
recurrence of HF symptoms. Kaplan–Meier estimates revealed
a probability of 66.0+8.2% for 5 year freedom from HF recur-
rence after VAD removal (Figure 3A). In the patient group that
underwent VAD removal before March 2002, HF recurred in
14 (45.2%) of 31 patients. Of these HF recurrences, nine
(64.3%) occurred during the ﬁrst year after weaning. In the
group weaned thereafter, only 3 (18.8%) of the 16 patients
showed HF recurrences, which all arose late, beyond the
fourth post-weaning year. There were no signiﬁcant differences
in post-weaning cardiac stability between patients who were
weaned from continuous ﬂow LVADs and those weaned from
pulsatile LVADs.
Of the 17 patients with HF recurrence, 15 underwent HTx, 1
patient (.65 years of age at HF recurrence) received another
LVAD designed as a chronic mechanical circulatory support, and
2 patients died suddenly 2.1 and 5.7 years after LVAD removal,
respectively.
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Table 2 Weaned patient characteristics at the time of ventricular assist device implantation: comparison of patients
who exhibited long-lasting cardiac stability with those showing heart failure recurrence during the ﬁrst 5 years after
ventricular assist device removal
Main characteristics All chronic HF patients
weaned from VADs
a
(n 5 47)
Patients evaluated for long-lasting recovery after VAD removal
a
(n 5 33
b)
Long-lasting cardiac
improvement
(>5 years) (n 5 19)
Post-weaning
recurrence of HF (in
≤5 years) (n 5 14)
P-value
Age (years) 42.4+14.4 40.1+12.1 47.6+9.7 0.03
c
Sex [n (%)]
Male 42 (95.5) 18 (94.7) 14 (100) 1.0
Female 2 (4.5) 1 (5.3) 0
Diagnosis [n (%)]
Non-ischaemic chronic CM 42 (95.5) 17 (89.5) 14 (100) 0.9
Ischaemic chronic CM 2 (4.5) 2 (10.5) 0
History of HF (years) 4.1+3.8 2.4+1.5 6.4+4.5 0.01
c
Patients with LVADs [n (%)] 42 (95.5) 18 (94.7) 13 (92.9) 1
Patients with BVADs [n (%)] 2 (4.5) 1 (5.3) 1 (7.1)
Heart rhythm [n (%)]
Sinus rhythm 43 (97.7) 19 (100) 13 (92.9) 0.42
Atrial ﬁbrillation 1 (2.3) 0 1 (7.1)
LVEF (%) 15.4+3.4 15.0+2.6 15.3+3.4 0.79
LVEDD (mm) 74.3+7.5 73.1+4.3 78.4+4.1 0.09
Fibrosis (%) 12.1+9.6 9.8+5.2 16.0+10.5 0.08
Serum A-b1-AABs (LU) 5.4+2.1 5.2+1.7 5.4+1.9 0.95
LU, laboratory units.
aValues are means+SD.
bOnly 33 of the 47 weaned patients with CCM could be used for comparison. Patients with stable cardiac function who died during the ﬁrst 5 post-weaning years due to different
causes not related to VAD removal and patients who were weaned ,5 years before this evaluation were not included.
cStatistically signiﬁcant.
M. Dandel et al. 1152Figure 1 Outcome after ventricular assist device (VAD) removal. Between 1995 and 2002, of the 31 weaned patients, 9 (marked with aster-
isk) had left ventricular ejection fraction values of between 30 and 44% at left ventricular end-diastolic diameter values of between 55 and
66 mm before VAD removal. All nine patients showed heart failure recurrence during the ﬁrst 10 post-weaning months. Therefore, thereafter
weaning was restricted to patients with left ventricular end-diastolic diameter ≤55 mm and left ventricular ejection fraction ≥45%.
Figure 2 Kaplan–Meier estimates of patient survival after ventricular assist device (VAD) removal. (A) Probability of overall post-weaning
survival with the inclusion of post-transplant survival for patients with recurrence of heart failure (HF). (B) Probability of post-weaning survival
from heart failure recurrence or weaning-related complications.
Heart failure reversal by ventricular unloading 1153Among the 19 patients without HF recurrence during the ﬁrst 5
post-weaning years, 16 (84.2%) were in functional NYHA class ≤II
at the end of the ﬁfth post-weaning year. Another two patients,
whoalsoshowedgoodcardiacfunction,werenotcapableofphysical
activities because of neurological sequels after cerebral vascular
accidentswhichoccurredbeforeVADremoval,andonepatientoscil-
latedbetweenNYHAclassIIandIII.Inthesepatients,exercisetesting
performed between the third and fourth year (3.5+0.5 years) after
weaning revealed onlyslightly or moderately reduced exercise toler-
ance. Expressed as a percentage of the predictive values, the
maximum oxygen uptake reached 77.3+4.5%, and the ventilatory
equivalent for CO2 was 29.7+3.5 in these patients. Patients with
.3 yearcardiacstabilityafterVADremovalshowedonlyslightlyelev-
ated NT-proBNP levels even late after weaning (159.8+91.7 pg/mL
at 6.5+2.3 years after weaning).
Comparison of patients with and without
recurrence of heart failure
Heart failure recurrence vs. cardiac stability during the
ﬁrst 5 post-weaning years
Data obtained from 33 patients who could be evaluated for long-
term (.5 years) post-weaning cardiac stability (weaning since
≥5 years and no deaths before the ﬁfth post-weaning year due to
causes other than HF recurrence) show that in patients with HF
recurrence during the ﬁrst 5 post-weaning years, the duration of
VAD support necessary for recovery was longer than in those
withpost-weaningcardiacstabilityfor .5 years(Table3).Inpatients
with post-weaning cardiac stability for .5 years, the LVEF was
higher and the LVEDD smaller before VAD removal than in the
patients with HF recurrence during the ﬁrst 5 post-weaning years
(P , 0.01). There were no differences in Doppler parameters or
Doppler-derived indices of diastolic function measured at ﬁnal
off-pump trials in patients with and without HF recurrence after
weaning. However, wall motion peak systolic velocities (Sm)
measured during the ﬁnal off-pump trials by pulsed-wave TDI
were higher in patients with stable post-weaning cardiac function
(Table 3). Patients with long-lasting post-weaning cardiac stability
also showed higher stability of Sm values before VAD removal (no
or ,10% reduction after maximum improvement and ≤10%
reduction during the ﬁnal off-pump trials in comparison with the
Sm measured with the working pump).
Between patients with and without HF recurrence during the
ﬁrst 5 post-weaning years, there were no differences for the disap-
pearance time of A-b1-AABs during VAD support (Table 3). There
were also no differences in PAP values (measured at the time of
VAD removal) between these two groups.
Comparison between patients weaned
before and after weaning protocol
changes
In the patient group that underwent VAD removal before March
2002, 11 (78.6%) of the 14 HF recurrences were during the
ﬁrst 5 years, whereas in the group with removal thereafter accord-
ing to a modiﬁed weaning protocol (no weaning if LVEF ,45%
and/or LVEDD .55%), there was no HF recurrence during the
ﬁrst 3 post-weaning years and only one patient showed HF recur-
rence before the end of the ﬁfth post-weaning year (Figure 3B).
Predictability of cardiac stability after
ventricular assist device removal
None of our weaned CCM patients with history lengths of HF
≤5 years before VAD implantation who at the time of VAD
removal had off-pump LVEF and LVEDD values of ≥45% and
≤55mm, respectively, showed recurrence of HF during the ﬁrst
3 post-weaning years and even cardiac stability beyond the ﬁfth
post-weaning year appeared predictable by these parameters.
Thus, pre-explantation off-pump LVEF of ≥50% appeared highly
predictive (91.7%) for cardiac stability lasting ≥5 years after VAD
Figure 3 Kaplan–Meier estimates of freedom from heart failure (HF) recurrence after ventricular assist device (VAD) removal. (A) Post-
weaning freedom from heart failure recurrence for all evaluated patients. (B) Comparison of 3 year post-weaning freedom from heart
failure recurrence between patients who were weaned from ventricular assist devices before and after March 2002.
M. Dandel et al. 1154removal and if the LVEDD and duration of HF were considered in
addition, high predictive values (up to 80%) were also obtained for
cardiac stability lasting ≥7 years after weaning (Table 4). Pre-
explantation off-pump LVEF of ≥45% also appeared predictive
for long-term post-weaning stability, especially in relation to LV
size, duration of HF, and stability of cardiac improvement before
VAD explantation. The highest predictive values for stability
lasting a minimum of 7 years after VAD removal in patients with
off-pump LVEF ≥ 45% were obtained in patients with history
lengths of HF of ≤5 years and stable LVEDD of ≤55 mm as well
as in patients with off-pump LVEF ≥45% who showed no LVEF
alterations during the ﬁrst month after VAD removal (positive pre-
dictive value 78.6 and 80%, respectively). A cut-off value of ≥40%
for pre-explantation off-pump LVEF showed relatively low predict-
ability for ≥5 year cardiac stability after LVAD removal even in
relation to other parameters such as LV size, LV relative wall thick-
ness (RWT), duration of HF, or pre-weaning stability of cardiac
improvement (predictive values ≤74%).
Radial or longitudinal off-pump Sm values ≥8 cm/s showed a
positive predictive value of 86.7% for post-weaning cardiac stability
during the ﬁrst 5 post-weaning years.
Major risk factors for recurrence of heart
failure after ventricular assist device
explantation
Patients with ≥5 year cardiac stability after VAD removal were
younger, and their duration of HF before VAD implantation was
shorter. The predictive value for HF recurrence during the ﬁrst
5 post-weaning years for HF duration of .5 years reached
88.9%. Although patients with post-weaning cardiac stability
showed less ﬁbrosis in myocardial specimens collected during
VAD implantation, the differences between stable and unstable
patients during the ﬁrst 5 post-weaning years were not statistically
signiﬁcant (Table 2).
At the time of VAD removal, patients with and without HF
recurrence during the ﬁrst 5 post-weaning years also showed
differences in LV size, geometry, and systolic function (Table 3).
Thus, in those with HF recurrence, the LV had larger end-diastolic
diameters, was more spherical, and showed lower RWT and EF.
There were also differences between patients with long-term post-
weaning stability and those with HF recurrence in the time course
of LVEDD and LVEF during mechanical unloading. Thus, patients
with post-weaning HF recurrence required longer mechanical
support for recovery and already showed partial reversibility of
cardiac improvement (LVEDD increase and/or LVEF worsening)
before LVAD removal. Patients with post-weaning HF recurrence
also had more RWT alterations (LVEDD increase and end-diastolic
wall thinning) during ﬁnal off-pump trials (Table 3). During the ﬁrst
month after LVAD removal, the time course of LVEF and LVEDD
was different between patients with and without cardiac stability
during the ﬁrst 3 post-weaning years. At the end of the ﬁrst post-
weaning month, all patients with HF recurrence during the ﬁrst 3
post-weaning years already had .10% lower LVEF values in com-
parison with the values measured at the time of VAD removal. Left
ventricular ejection fraction reduction during the ﬁrst month of
.......................................................................................
...............................................................................................................................................................................
Table 3 Patient characteristics at the time of ventricular assist device explantation: comparison of patients who
exhibited long-lasting cardiac stability with those showing heart failure recurrence during the ﬁrst 5 years after
ventricular assist device removal
Patient characteristics All chronic HF patients
weaned from VADs
a
(n 5 47)
Patients evaluated for long-lasting recovery after VAD removal
a
(n 5 33
b)
Long-lasting cardiac
improvement (>5 years)
(n 5 19)
Post-weaning recurrence
of HF (in ≤5 years)
(n 5 14)
P-value
LVEF (%) 47.2+6.8 49.2+2.6 42.4+3.4 ,0.01
LVEF change (% of best value) 27.7+9.6 24.2+4.4 216.2+19.5 ,0.001
LVEDD (mm) 52.2+7.5 49.2+3.9 56.2+5.9 ,0.01
LVEDD change (% of best value) 9.0+9.6 4.7+3.5 16.9+6.3 ,0.001
RWT 0.39+0.07 0.42+0.04 0.35+0.04 ,0.001
Sm (cm/s) posterior wall, radial 8.5+1.3 9.5+2.2 7.0+1.9 ,0.01
Sm (cm/s) posterior wall, longitudinal 8.8+1.4 9.8+2.6 7.3+1.5 ,0.01
RWT change during off-pump trials (%) 8.6+6.9 25.5+3.5 215.8+0.4 ,0.001
LV sphericity Index (short-/long-axis ratio) 0.66+0.07 0.64+0.09 0.72+0.07 0.05
Duration of LVAD support (months) 4.9+2.8 3.5+2.1 6.7+5.2 0.02
Time (months) to disappearance of serum
A-b1-AABs
c
2.6+0.3 2.5+1.7 2.6+1.9 0.90
d
aValues are means+SD.
bOnly 33 of the 47 weaned patients with CCM could be used for comparison. The six patients with stable cardiac function who died during the ﬁrst 5 post-weaning years due to
different causes not related to VAD removal and patients who were weaned ,5 years before this evaluation were not included.
cAnti-b1-adrenoceptor auto-antibodies.
dStatistically not signiﬁcant.
Heart failure reversal by ventricular unloading 1155.10% of pre-weaning values showed a predictive value of 84.6 and
91.7% for HF recurrence during the ﬁrst 3 and 5 years,
respectively.
Our data revealed several risk factors for HF recurrence
(Table 4; Figure 4). At certain cut-off values which provide the best-
balanced sensitivity and speciﬁcity, the presence of these risk
factors appeared associated with high probabilities for HF recur-
rence. Pre-explantation off-pump LVEF ,45%, LVEDD .55 mm,
and LV end-diastolic RWT ,0.37, as well as end-diastolic RWT
decrease of .10% during the ﬁnal off-pump trials revealed high
predictive values for HF recurrence (Table 5). Also, LVEF and/or
LVEDD alterations of .10% of the best off-pump value (i.e.
off-pump LVEF reduction and/or LVEDD increase after their
improvement has reached the optimal values, at the time of
VAD removal already showing alterations of .10% in comparison
with their best values), as well as history lengths of HF .5 years
appeared to be risk factors for weaning. In our patient cohort,
LV sphericity indexes of .0.67 or prolonged VAD support time
of ≥6 months also revealed relevant positive predictive value for
HF recurrence during the ﬁrst 5 post-weaning years of 84.6 and
72.7%, respectively. Left ventricular ejection fraction of ,40%
showed a 100% predictive value for HF recurrence already
during the ﬁrst 3 post-weaning years. Univariate logistic regression
analysis (Table 6) conﬁrmed the relevance of several risk factors for
HF recurrence. Thus, with each unit of LVEF reduction, the risk for
HF recurrence became 1.49 times higher, and with each year of
longer history of heart disease before VAD implantation, the risk
for post-weaning HF recurrence appeared to be 1.62 times
higher. Also with each unit of early post-weaning alteration of
LVEF during the ﬁrst month after VAD removal, the risk for HF
recurrence was 1.31 times higher. Cox regression analysis also
conﬁrmed the importance of these risk factors yielding for the
duration of HF before VAD implantation, the ﬁnal off-pump
LVEF and LVEDD measured before VAD removal, and the
pre-VAD-explantation instability of LVEF and LVEDD (alterations
of .10% in comparison with the best off-pump values) P-values
of ≤0.001.
Discussion
To date, published studies have reported only small numbers of
patients with chronic HF who underwent VAD removal after
different degrees of cardiac improvement.
2,5,13,19 Beside the low
rate of relevant improvement, which might in principle allow
patients to be weaned from VADs, the limited long-term
outcome data after weaning and the lack of data on predictability
of weaning results are major contributors to the low number of
VAD explantations performed in patients with chronic HF. Our
data conﬁrm previous observations that unloading-induced
cardiac improvement occurs more frequently in patients with non-
ischaemic CCM and only occasionally in those with ischaemic
CCM.
2,13 The proportion of our patients with non-ischaemic
CCM who were weaned from VADs reached 18%, whereas that
of patients with ischaemic CCM who were weaned from VADs
was ,1%. The impact of the VAD type, i.e. pulsatile or continuous
ﬂow pumps, on the rate of unloading-induced myocardial recovery
.........................................................................................................................
........................................................... ...........................................................
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...............................................................................................................................................................................
Table 4 Echocardiographic prediction of post-weaning cardiac stability in patients with chronic cardiomyopathy as the
underlying cause for ventricular assist device implantation
Selected parameters and cut-off
values
Prediction of freedom from HF recurrence
For ≥5 years For ≥7 years
Sensitivity
(%)
Speciﬁcity
(%)
Predictive
value (%)
Sensitivity
(%)
Speciﬁcity
(%)
Predictive
value (%)
Final
a off-pump LVEF ≥50% 55.0 92.3 91.7 57.1 77.8 66.7
at LVEDD ≤55 mm 55.0 100 100 57.1 83.3 72.7
plus history of HF ≤5 years 50.0 100 100 57.1 88.9 80.00
Final
a off-pump LVEF 45% 95.0 61.5 79.4 100 50.00 60.9
plus pre-weaning LVEF stability
b 90.0 76.9 85.7 92.9 61.1 65.00
at LVEDD ≤55 mm 95.0 76.9 86.4 100 61.1 66.7
at LVEDD ≤55 mm plus pre-weaning
LVEDD stability
b
80.0 92.3 94.1 78.6 72.2 68.8
at LVEDD ≤55 mm plus pre-weaning
LVEF and LVEDD stability
b
80.0 92.3 94.1 78.6 71.4 73.3
plus history of HF ≤5 years 90.0 76.9 85.7 100 72.2 73.7
at LVEDD ≤55 mm with pre-weaning
stability
b plus history of HF ≤5 years
85.0 100 100 78.6 83.3 78.6
without alteration during the ﬁrst
post-weaning month
c
90.0 84.6 90.0 92.9 61.1 65.0
aLast pump-stop before VAD explantation.
bNot more than 10% alteration in comparison with the best of all off-pump values until VAD removal.
cNot more than 10% alteration in comparison with LVEF at VAD removal.
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weaned 24.4% of those who had pulsatile LVADs and only 9.2%
of those who had continuous ﬂow LVADs. This relatively low inci-
dence of relevant myocardial recovery in patients with non-
pulsatile LVADs is similar to that reported by other groups who
investigated only patients with rotary pumps.
13 In our patients,
the great differences in recovery rates are in part induced by the
more restrictive weaning criteria which were introduced after
the current use of non-pulsatile devices. However, even without
the nine patients with insufﬁcient recovery (LVEF ,45% and/or
LVEDD .55 mm) who were weaned from pulsatile LVADs, the
prevalence of non-ischaemic CCM patients with unloading-induced
recovery remained relatively high (17.5%). Despite these differ-
ences in recovery rates, the post-weaning cardiac stability
appeared not related to the type of VAD which promoted the ven-
tricular recovery.
Post-weaning 5 year freedom from HF recurrence in our CCM
patients reached 66%, although only four (8.7%) of these patients
had pre-explantation off-pump LVEF of .50%. Of the three
patients with post-weaning cardiac stability of .14 years, two
had pre-explantation LVEF of only 45 and 46%, respectively.
Only few patients died due to HF recurrence or VAD
explantation-related complications. With the option of HTx, 24
of 33 (72.7%) patients who were weaned from VADs before
2004 were alive at the end of the ﬁfth post-weaning year (79.2%
of them with their native hearts). This survival rate is better than
that expected after HTx.
24 All these data support the supposition
that complete cardiac recovery is not indispensable for VAD
explantation and that weaning is feasible without normalization
of cardiac function.
2,9,11,16
Heart failure recurrence appeared to be the most frequent com-
plication after VAD removal and therefore, further improvement of
post-weaning patients’ outcome will depend mainly on better pre-
diction of post-weaning cardiac stability. To improve future
weaning decisions in patients with CCM as the underlying cause
of VAD insertion, the present study also focused on the potential
prediction of post-weaning cardiac stability. We identiﬁed several
risk factors for post-weaning HF recurrence and found that
certain cut-off values for some pre-explantation off-pump par-
ameters related to LV size, geometry, and function, as well as
the duration of HF before VAD implantation allow the distinction
between patients with and without the potential to maintain
cardiac stability for more than 5 or even more than 7 years after
weaning. Altered LV geometry appeared to be a potential risk
factor for HF recurrence even in patients with pre-weaning LVEF
≥45%. Also, LV end-diastolic RWT decrease of .10% during pre-
explantation off-pump trials appeared to be a risk factor for HF
recurrence. This is not surprising because RWT reduction is
associated with wall stress increase.
25 According to our data, dur-
ation of HF of .5 years and to a lesser extent also the duration of
Figure 4 Distribution of selected major risk factors for heart failure recurrence in patient groups with and without recurrence of heart failure
(HF) during the ﬁrst 5 post-weaning years.
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Table 5 Risk factors for heart failure recurrence after ventricular assist device removal in patients with chronic cardiomyopathy who showed myocardial
improvement during ventricular unloading
Major risk factors HF recurrence after weaning
During ﬁrst 3 years During ﬁrst 5 years During ﬁrst 7 years
Events with
risk factors
Number of
events with risk
factors
Predictive
value (%)
Events with
risk factors
Number of
events with risk
factors
Predictive
value (%)
Events with
risk factors
Number of
events with risk
factors
Predictive
value (%)
Off-pump LVEF ,45% 8 1 88.9 8 1 88.9 9 0 100
Off-pump LVEF ,45% plus
history of HF .5 years
7 0 100 7 0 100 7 0 100
Off-pump LVEF ,50 and .10%
alteration to the best off-pump
value
7 1 88.0 8 0 100 8 0 100
Off-pump LVEF ≤50% at LVEDD
.55 mm plus history of HF
.5 years
8 0 100 8 0 100 8 0 100
Off-pump LVEF ≤50% at LVEDD
.55 mm
9 1 90.0 9 1 90.00 10 0 100
Off-pump LVEF ≤50% plus RWT
≤0.37
10 2 83.3 11 1 91.7 12 0 100
Off-pump LVEF ≤50% with RWT
decrease with .10% during
off-pump trials
10 2 83.3 11 1 91.7 11 1 91.7
Early post-weaning LVEF
alteration with .10%
11 2 84.6 11 2 91.7 11 1 91.7
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8mechanical support of .6 months until maximum cardiac
improvement are potential risk factors for HF recurrence, but
these parameters appeared not to be a contraindication for VAD
removal if pre-weaning LVEF and LVEDD are ≥45% and
≤55 mm, respectively. Also the early instability of unloading-
induced cardiac improvement appeared to be a relevant risk
factor for HF recurrence after VAD removal. Thus, if after
maximum improvement further unloading is followed by LVEF
alteration and/or LVEDD increase of .10% of best value, the
risk of HF recurrence is high.
Pre-explantation off-pump LVEF ,40%, regardless of the pres-
ence or absence of any other additional risk factor, appeared to
be 100% predictive for early recurrence of HF. The same 100%
predictive value for early HF recurrence was found for
off-pump LVEF ,45% in patients with a history of HF
.5 years and also for off-pump LVEF ≤50% with LVEDD
.55 mm plus a history of HF .5 years. The importance of
LVEF and LVEDD for the post-weaning outcome was conﬁrmed
by the fact that in our patients who underwent VAD removal
after March 2002, when the new weaning protocol meant that
only patients with off-pump LVEF ≥45% and LVEDD ≤55 mm
were selected for VAD explantation, there was no HF recur-
rence during the ﬁrst 3 years after VAD removal and only one
patient showed HF recurrence before the end of the ﬁfth post-
weaning year. However, to date, only 50% of the patients
weaned after 2002 reached post-weaning times of ≥3 years
and therefore at present there is no certainty that our weaning
criteria used after 2002 can protect all patients from early recur-
rence of HF.
Prediction of post-weaning long-term cardiac stability also
became possible. The highest predictive values for .5 year
cardiac stability were found for pre-explantation off-pump LVEF
≥50% either with LVEDD ≤55 mm or with a history of HF
≤5 years and also for LVEF ≥45% accompanied by LVEDD
≤55 mm with pre-weaning stability plus a history of HF
≤5 years (Table 4). The highest predictability for .7 year cardiac
stability was found for pre-explantation off-pump LVEF ≥50%
with LVEDD ≤55 mm. However, cardiac stability beyond the
seventh post-weaning year appeared less predictable at the time
of VAD removal.
All patients without HF recurrence after weaning showed systo-
lic wall motion peak velocities (Sm)o f.8 cm/s at the basal pos-
terior wall. Sm values of ≥8 cm/s showed 86.7% predictive value
for cardiac stability during the ﬁrst 5 post-weaning years. The rela-
tively high predictive value of Sm for cardiac stability after weaning
is not surprising. Because the ﬁnal part of ejection occurs by iner-
tial effects after myocyte contraction is ﬁnished, Sm, like peak sys-
tolic global strain rate, being an early systolic event, is more closely
related to contractility than the EF, and impaired systolic function
can be detected earlier by Sm than by EF measurements.
26,27
Nevertheless, our data available at present are insufﬁcient for
reliable conclusions and the predictive value of tissue Doppler par-
ameters remains to be ﬁnally established by future studies.
The time course of LVEDD and LVEF early after weaning
showed important prognostic value. Therefore, more frequent
follow-up examinations during the ﬁrst weeks after weaning are
paramount.
Before VAD implantation, we found no parameters which might
be able to predict the reversibility of myocardial damage and the
improvement of heart function during mechanical unloading.
Unloading-induced normalization of LV diameters and improve-
ment of LVEF up to 50% were uncommon in patients with a
history of HF of .5 years and/or large amount of interstitial ﬁbro-
sis (.22%) at the time of VAD implantation. Nevertheless, accord-
ing to our observations, even in such patients relevant and stable
cardiac improvement is not impossible. The use of new immuno-
histochemistry techniques for the analysis of collagen content
and evaluation of different collagen components, gene expression
analyses, distribution of myocyte adrenoreceptors, and more sen-
sitive methods for the evaluation of LV function like strain and
strain rate imaging might help predict the reversibility of myocardial
alterations during mechanical unloading.
2,26,28
Limitations
Data were obtained from a single-centre retrospective study of
prospectively gathered information. The still relatively small
cohort and the lack of randomization also limited our study.
However, these limitations were unavoidable because weaning is
not possible in patients without relevant myocardial improvement.
Also, the small number of patients with recurrence of HF after
VAD removal restricted the possibilities for additional statistical
evaluation like reliable multivariate analysis.
Conclusions
Weaning from VADs is a clinical option with potentially successful
results for .15 years in patients with CCM even with incomplete
cardiac regeneration during unloading. Off pump echocardio-
graphic data are reliable for the assessment of cardiac improve-
ment and for weaning decisions. Pre-explantation LVEF, LV
systolic wall motion peak velocity (Sm), end-diastolic LV diameter
and RWT, pre-weaning stability of unloading-induced cardiac
improvement, and duration of HF before VAD implantation
allow the distinction between patients with and without the poten-
tial to maintain cardiac stability for .5 years and even .7 years
after weaning.
................................................................................
Table 6 Relevance of main risk factors for heart
failure recurrence
Selected risk factors for HF
recurrence
Odds
ratio
a
95% CI P-value
Final off-pump LVEF 1.49 1.12–1.98 0.007
Pre-weaning LVEF stability
b 1.18 1.04–1.35 0.014
Final off-pump LVEDD 1.26 1.06–1.50 0.010
Pre-weaning LVEDD stability
b 1.19 1.05–1.34 0.006
Duration of HF before VAD
support
1.62 1.09–2.41 0.016
aRisk for HF with alteration by one unit.
bNot more than 10% alteration in comparison with the best of all off-pump values
until VAD removal.
Heart failure reversal by ventricular unloading 1159The early post-weaning time course of LVEF is helpful in prog-
nostic assessment.
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